Mammary Cell News Volume 12.10 | Mar 19 2020

TOP STORY

Rac1 Activates Non-Oxidative Pentose Phosphate Pathway to Induce Chemoresistance of Breast Cancer

Rac1 activated aldolase A and ERK signaling which up-regulated glycolysis and especially the non-oxidative pentose phosphate pathway. This led to increased nucleotides metabolism which protected breast cancer cells from chemotherapeutic-induced DNA damage. [Nat Commun] Full Article

(Ranked by impact factor of the journal)

Infiltrating Mast Cell-Mediated Stimulation of Estrogen Receptor Activity in Breast Cancer Cells Promotes the Luminal Phenotype

When co-cultured with breast cancer cells in vitro, mast cells hindered activation of cMET, a master regulator of the basal program, and simultaneously promoted expression and activation of estrogen receptors and its target genes, which were all luminal markers. [Cancer Res] Abstract

A Model of Differential Mammary Growth Initiation by Stat3 and Asymmetric Integrin-α6 Inheritance

Stat3 inhibition randomized spindle orientation, which promoted normal growth initiation while reducing tumor-derived growth initiation. Lipid raft disruption depolarized integrin-α6, inducing spindle-orientation-independent integrin-α6 inheritance. [Cell Rep] Full Article | Graphical Abstract

ECM1 Secreted by HER2-Overexpressing Breast Cancer Cells Promotes Formation of a Vascular Niche Accelerating Cancer Cell Migration and Invasion

The authors analyzed epithelial-endothelial cross talk in the breast using isogenic non-tumorigenic vs. tumorigenic breast epithelial cell lines and primary endothelial cells. [Lab Invest] Abstract

RUNX1 and RUNX2 Transcription Factors Function in Opposing Roles to Regulate Breast Cancer Stem Cells

Scientists developed a model system to mechanistically examine breast cancer stem cells in basal-like breast cancer using MCF10AT1 FACS sorted for CD24 and CD44. [J Cell Physiol] Abstract

Development and Characterization of Mammary Intraductal (MIND) Spontaneous Metastasis Models for Triple-Negative Breast Cancer in Syngeneic Mice

Researchers demonstrated that 4T1-MIND model mice injected with 20,000 cells revealed a suitable tumor formation rate and time, thus indicating a potential treatment time window after distant metastasis. [Sci Rep] Full Article

Ribitol Enhances Matriglycan of α-Dystroglycan in Breast Cancer Cells without Affecting Cell Growth

Ribitol was able to significantly enhance the expression of matriglycan on α-dystroglycan in breast cancer cells. The ribitol effect was associated with an increase in levels of CDP-ribitol, the substrate for the ribitol-5-phosphate transferases FKRP and FKTN. [Sci Rep] Full Article

Long Noncoding RNA LINC00115 Promotes Breast Cancer Metastasis by Inhibiting miR-7

Investigators report that LINC00115 expression was increased in triple‐negative breast cancer tissue compared with matched normal tissue, and LINC00115 knockdown suppressed breast cancer cell migration and invasion. [FEBS Open Bio] Abstract

SOX2 Promotes Brain Metastasis of Breast Cancer by Upregulating the Expression of FSCN1 and HBEGF

Overexpression of SOX2 in breast cancer cells enhanced cancer cell adhesion to brain microvascular endothelial cells, transendothelial migration and in vitro blood-brain barrier migration, whereas silencing SOX2 inhibited these events. [Mol Ther Oncolytics] Abstract | Full Article | Graphical Abstract

Single-Cell RNA Sequencing Reveals a Heterogeneous Response to Glucocorticoids in Breast Cancer Cells

Single cell RNA sequencing revealed striking cell-to-cell variability in the hormone response. On average, individual hormone-treated cells showed a response at only 30% of the total set of glucocorticoid receptor target genes. [Commun Biol] Full Article

Subscribe to one of our other 19 science newsletters such as Prostate Cell News & ESC & iPSC News.

The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer

Investigators discuss the most relevant cyclin-dependent kinase inhibitors currently in clinical breast cancer trials, with special emphasis on CDK4/6 inhibitors used for the treatment of estrogen receptor-positive/human epidermal growth factor 2-negative advanced or metastatic breast cancer patients, as well as more emerging precise therapeutic strategies, such as combination therapies and miRNA therapy. [Int J Mol Sci] Full Article

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Tyligand Bioscience and Context Therapeutics Sign Strategic Development Agreement for Onapristone ER

Tyligand Bioscience, Ltd. announced the signing of collaboration agreements for the development, manufacturing, registration and future commercialization of onapristone extended release (ER). [Tyligand Bioscience, Ltd.] Press Release

Teva and Celltrion Healthcare Announce US Availability of HERZUMA^® (Trastuzumab-Pkrb) for Injection

Teva Pharmaceuticals USA, Inc. and Celltrion Healthcare, Co., Ltd. announced that HERZUMA^® for Injection, a biosimilar to HERCEPTIN^®, is now available in the United States. [Teva Pharmaceuticals USA, Inc. (Business Wire, Inc.)] Press Release

Respirators, Quarantines, and Worst-Case Scenarios: Lab Animal Facilities Grapple with the Pandemic

Many universities are currently grappling with the best way to care for the millions of mice, monkeys, and other research animals they care for across the country, in addition to protecting the health of their own employees. [ScienceInsider] Editorial

Journals, Peer Reviewers Cope with Surge in COVID-19 Publications

Academic journals have already taken steps to accelerate the flow of peer-reviewed information by expediting editorial and peer review for coronavirus-related manuscripts and granting them open-access status upon publication. [The Scientist] Editorial

Near-Lockdown in the Bay Area ‘Ratchets Up’ Challenges for Local Biotechs and Labs

Seven counties in the San Francisco Bay Area went into near-lockdown — ushering in a new reality for biopharma companies and biomedical labs. The “shelter in place” order offers significant leeway for medical research. [STAT News] Editorial

In light of COVID-19, many conferences are being cancelled or postponed. As such:

We are suspending new event postings in our newsletters and on Twitter.
We will strive to keep our current event listings updated with event status.
We encourage you to visit event sites directly for updates.

Visit our events page to see a complete list of events in the community.

NEW Research Fellow – Breast Cancer (Dana-Farber Cancer Institute)

NEW Postdoctoral Position – Cancer Genomics and Epigenomics Research (NIH National Cancer Institute)

NEW Postdoctoral Fellow – RAS Cancer Cell Biology (University of Luxembourg)

NEW Group Leaders – Cancer Biology (Institute of Pharmacology and Structural Biology)

Postdoctoral Training Fellow – Endocrine Control Mechanisms (Institute of Cancer Research)

Postdoctoral Investigator – Breast Cancer Cell Biology (Florida Atlantic University)

Research Assistant – 3D Models of Breast Cancer (University of Cambridge)

Postdoctoral Research Position – Breast Cancer Research (The University of Texas)

Postdoctoral Position – Breast Cancer Metastasis (University of Kentucky)

Postdoctoral Fellow – Breast Tumorigenesis (University of Cincinnati)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.